Uli Stilz joined Flagship Pioneering in 2026 and serves as Senior Partner, Pioneering Medicines Partnerships, where he focuses on advancing Flagship’s global ecosystem partnerships and innovation collaborations across company creation, platform innovation, and asset development. His work includes shaping next-generation partnership models, expanding Flagship’s Innovation Supply Chain (ISC) collaborations, and strengthening Flagship’s engagement across the global biopharmaceutical ecosystem.

Uli joined Flagship after more than three decades of leadership across the global pharmaceutical and biotechnology industries, spanning scientific innovation, R&D strategy, and external innovation. He has extensive experience building and scaling therapeutics platforms and companies at the intersection of emerging biology, new modalities, and AI, translating scientific breakthroughs into durable therapeutic impact.

Before joining Flagship, Uli was Corporate Vice President at Novo Nordisk, where he led External Innovation globally. Prior to this role, he founded and scaled the Bio Innovation Hub, creating a venture-style R&D platform that built a multi-asset portfolio with a strong emphasis on first-in-class programs and novel modalities, contributing significantly to Novo Nordisk’s early-stage pipeline. Earlier in his career, he held senior scientific and innovation leadership roles at Sanofi and Novo Nordisk, contributing to more than 60 development candidates, including 30 INDs, across cardiometabolic disease, immunology, and oncology.

Uli serves on the Board of Aerska Therapeutics and is Chair of the Scientific Advisory Board at CaVos. He is also Vice Chair of the Kendall Square Association and serves as a Strategic Advisor to Jefferson Life Sciences and other investment organizations. Previously, he served as President of the European Federation for Medicinal Chemistry (EFMC) and was recognized as an EFMC Honoree in 2020 and a Fierce 50 Innovation Honoree in 2024.

Uli trained in organic chemistry at ETH Zürich and earned his Ph.D. at the Max Planck Institute of Biochemistry under Nobel laureate Hartmut Michel and Professor Dieter Oesterhelt. He subsequently completed postdoctoral research at the California Institute of Technology (Caltech) with Peter Dervan.

Rajesh Ramaswamy is building the next generation of intelligent systems that transform how we understand, predict, and engineer complex systems across health, finance, and the physical world. His work focuses on turning traditionally empirical disciplines into continuously learning, AI-driven systems that improve with every interaction. Across startups, growth-stage companies, and global enterprises, he has led the development and deployment of AI systems that deliver measurable scientific, operational, and commercial impact.

He is currently Head of AI at Precede Biosciences, where he leads the strategy, development, and deployment of foundational AI systems for diagnostics and data products. His work is focused on transforming blood into a continuously updated representation of human biology, enabling earlier and more precise interventions, and ultimately a shift from reactive to adaptive healthcare. By combining multimodal data, machine learning, and scalable AI infrastructure, he is helping build systems capable of decoding complex diseases from genomic signals in blood at population scale.

Previously, Rajesh was Senior Vice President and Founding Head of AI at Sail Biomedicines, where he led the design and deployment of the company’s AI system for generating medicines. His work advanced a shift in drug creation from a process driven by chance to one grounded in engineering, where outcomes can be systematically improved and accelerated. The AI platform he helped pioneer contributed to multiple programs, including an in vivo CAR-T program.

Earlier, Rajesh founded and built the Data Driven Innovation office at EMD Serono, the North American biopharma business of Merck KGaA. There, he established enterprise AI capabilities and applied machine learning across the organization, enabling more effective commercial strategies and contributing to billion+ dollar product launches in Neurology, Immunology, and Oncology.

Rajesh began his career in quantitative finance, where he developed machine learning systems operating at the scale of billions of options trades per day across global markets.

He holds a Ph.D. in Computer Science from ETH Zürich, Switzerland.